Symbols / SLDB $7.76 +3.74%
SLDB Chart
About
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 604.58M |
| Enterprise Value | 368.56M | Income | -167.14M | Sales | — |
| Book/sh | 2.80 | Cash/sh | 3.03 | Dividend Yield | — |
| Payout | 0.00% | Employees | 100 | IPO | — |
| P/E | — | Forward P/E | -3.85 | PEG | — |
| P/S | — | P/B | 2.77 | P/C | — |
| EV/EBITDA | -2.19 | EV/Sales | — | Quick Ratio | 6.50 |
| Current Ratio | 6.74 | Debt/Eq | 10.06 | LT Debt/Eq | — |
| EPS (ttm) | -2.48 | EPS next Y | -2.01 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-17 | ROA | -43.67% |
| ROE | -86.83% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 77.91M |
| Shs Float | 41.22M | Short Float | 14.55% | Short Ratio | 8.31 |
| Short Interest | — | 52W High | 8.72 | 52W Low | 2.41 |
| Beta | 2.76 | Avg Volume | 1.33M | Volume | 1.62M |
| Target Price | $16.25 | Recom | Strong_buy | Prev Close | $7.48 |
| Price | $7.76 | Change | 3.74% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.25
Mean price target
2. Current target
$7.76
Latest analyst target
3. DCF / Fair value
$-17.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.76
Low
$11.00
High
$20.00
Mean
$16.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-12 | main | Wedbush | Outperform → Outperform | $17 |
| 2026-03-12 | main | Chardan Capital | Buy → Buy | $15 |
| 2026-03-11 | reit | Wedbush | Outperform → Outperform | $14 |
| 2026-02-09 | reit | Needham | Buy → Buy | $16 |
| 2026-01-14 | reit | Needham | Buy → Buy | $16 |
| 2025-12-04 | init | Needham | — → Buy | $16 |
| 2025-11-05 | main | Citigroup | Buy → Buy | $14 |
| 2025-11-05 | main | JP Morgan | Overweight → Overweight | $11 |
| 2025-11-04 | main | Barclays | Overweight → Overweight | $9 |
| 2025-11-04 | main | Chardan Capital | Buy → Buy | $15 |
| 2025-08-14 | main | Chardan Capital | Buy → Buy | $15 |
| 2025-08-14 | main | JP Morgan | Overweight → Overweight | $13 |
| 2025-08-13 | main | Wedbush | Outperform → Outperform | $14 |
| 2025-06-26 | init | Citigroup | — → Buy | $14 |
| 2025-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-06-06 | reit | JMP Securities | Market Outperform → Market Outperform | $15 |
| 2025-05-19 | main | Chardan Capital | Buy → Buy | $15 |
| 2025-05-16 | main | Piper Sandler | Overweight → Overweight | $17 |
| 2025-05-16 | main | Wedbush | Outperform → Outperform | $17 |
| 2025-05-16 | main | Barclays | Overweight → Overweight | $10 |
- RA Capital boosts Solid Biosciences (SLDB) ownership to 9.9% with March buys - Stock Titan ue, 17 Mar 2026 22
- Boxer Capital Management LLC Takes Position in Solid Biosciences Inc. $SLDB - MarketBeat Sun, 15 Mar 2026 11
- The Technical Signals Behind (SLDB) That Institutions Follow - Stock Traders Daily Sun, 15 Mar 2026 19
- Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start (NASDAQ:SLDB) - Seeking Alpha hu, 12 Mar 2026 19
- SLDB: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus hu, 12 Mar 2026 15
- $SLDB stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Wed, 14 Jan 2026 08
- Citizens reiterates Solid Biosciences stock rating on trial data By Investing.com - Investing.com Nigeria Mon, 16 Mar 2026 12
- Ally Bridge Group NY LLC Has $3.39 Million Stock Position in Solid Biosciences Inc. $SLDB - MarketBeat Sun, 15 Mar 2026 07
- Genetic medicines maker Solid Biosciences raises $240M from Perceptive and Bain - Stock Titan Fri, 06 Mar 2026 08
- Solid Biosciences (SLDB): Chardan Capital Maintains Buy Rating w - GuruFocus hu, 12 Mar 2026 13
- Solid Bio falls amid new data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha Wed, 11 Mar 2026 17
- $SLDB stock is down 10% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Feb 2026 08
- Solid Biosciences (NASDAQ: SLDB) reports promising SGT-003 Duchenne data - Stock Titan Wed, 11 Mar 2026 21
- Solid Biosciences (NASDAQ:SLDB) Shares Down 6.3% - Time to Sell? - MarketBeat Wed, 11 Mar 2026 18
- Wedbush Reiterates Outperform Rating for SLDB with $14 Price Tar - GuruFocus Wed, 11 Mar 2026 14
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 7469 | 43494.0 | — | Sale at price 5.82 per share. | HOWTON DAVID TYRONNE | Chief Operating Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 16644 | 96923.0 | — | Sale at price 5.82 per share. | CUMBO ALEXANDER | Chief Executive Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 2658 | 15478.0 | — | Sale at price 5.82 per share. | GANOT ILAN | Director | — | 2026-02-18 00:00:00 | I |
| 3 | 5404 | 31469.0 | — | Sale at price 5.82 per share. | TAN KEVIN | Chief Financial Officer | — | 2026-02-18 00:00:00 | D |
| 4 | 4134 | 24074.0 | — | Sale at price 5.82 per share. | HANRAHAN JESSIE | Officer | — | 2026-02-18 00:00:00 | D |
| 5 | 3616 | 21057.0 | — | Sale at price 5.82 per share. | HERZICH PAUL | Chief Technology Officer | — | 2026-02-18 00:00:00 | D |
| 6 | 89466 | 529639.0 | — | Sale at price 5.92 per share. | BROOKS GABRIEL M.D. | Officer | — | 2026-02-18 00:00:00 | D |
| 7 | 14687 | nan | — | — | HOWTON DAVID TYRONNE | Chief Operating Officer | — | 2026-02-13 00:00:00 | D |
| 8 | 30031 | nan | — | — | CUMBO ALEXANDER | Chief Executive Officer | — | 2026-02-13 00:00:00 | D |
| 9 | 4861 | nan | — | — | GANOT ILAN | Director | — | 2026-02-13 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -117.15M | -93.06M | -107.92M | -69.29M |
| TotalUnusualItems | -4.75M | 63.00K | 11.06M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -4.75M | 63.00K | 11.06M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -124.70M | -96.02M | -85.98M | -72.19M |
| ReconciledDepreciation | 2.46M | 2.58M | 2.41M | 2.96M |
| EBITDA | -121.90M | -92.99M | -96.87M | -69.29M |
| EBIT | -124.36M | -95.58M | -99.27M | -72.25M |
| NetInterestIncome | 9.13M | 7.14M | 2.62M | 64.00K |
| InterestExpense | 340.00K | 440.00K | ||
| InterestIncome | 9.47M | 7.58M | 2.62M | 64.00K |
| NormalizedIncome | -119.95M | -96.08M | -97.04M | -72.19M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -124.70M | -96.02M | -85.98M | -72.19M |
| TotalExpenses | 129.73M | 104.31M | 107.37M | 85.87M |
| TotalOperatingIncomeAsReported | -129.73M | -104.25M | -106.45M | -72.25M |
| DilutedAverageShares | 40.82M | 19.88M | 8.51M | 7.12M |
| BasicAverageShares | 40.82M | 19.88M | 8.51M | 7.12M |
| DilutedEPS | -3.06 | -4.83 | -10.10 | -10.14 |
| BasicEPS | -3.06 | -4.83 | -10.10 | -10.14 |
| DilutedNIAvailtoComStockholders | -124.70M | -96.02M | -85.98M | -72.19M |
| NetIncomeCommonStockholders | -124.70M | -96.02M | -85.98M | -72.19M |
| NetIncome | -124.70M | -96.02M | -85.98M | -72.19M |
| NetIncomeIncludingNoncontrollingInterests | -124.70M | -96.02M | -85.98M | -72.19M |
| NetIncomeContinuousOperations | -124.70M | -96.02M | -85.98M | -72.19M |
| PretaxIncome | -124.70M | -96.02M | -85.98M | -72.19M |
| OtherIncomeExpense | -4.10M | 1.16M | 10.68M | 2.00K |
| OtherNonOperatingIncomeExpenses | 652.00K | 1.09M | -381.00K | 2.00K |
| SpecialIncomeCharges | 0.00 | 63.00K | 11.06M | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | -63.00K | -11.06M | 0.00 |
| GainOnSaleOfSecurity | -4.75M | |||
| NetNonOperatingInterestIncomeExpense | 9.13M | 7.14M | 2.62M | 64.00K |
| TotalOtherFinanceCost | -2.62M | -64.00K | ||
| InterestExpenseNonOperating | 340.00K | 440.00K | ||
| InterestIncomeNonOperating | 9.47M | 7.58M | 2.62M | 64.00K |
| OperatingIncome | -129.73M | -104.31M | -99.27M | -72.25M |
| OperatingExpense | 129.73M | 104.31M | 107.37M | 85.87M |
| ResearchAndDevelopment | 96.43M | 76.56M | 78.42M | 58.74M |
| SellingGeneralAndAdministration | 33.30M | 27.75M | 28.95M | 27.14M |
| GeneralAndAdministrativeExpense | 33.30M | 27.75M | 28.95M | 27.14M |
| OtherGandA | 33.30M | 27.75M | 28.95M | 27.14M |
| TotalRevenue | 0.00 | 0.00 | 8.09M | 13.62M |
| OperatingRevenue | 0.00 | 0.00 | 8.09M | 13.62M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 40.47M | 20.39M | 19.56M | 7.36M |
| ShareIssued | 40.47M | 20.39M | 19.56M | 7.36M |
| TotalDebt | 24.18M | 26.27M | 28.55M | 2.06M |
| TangibleBookValue | 137.25M | 126.48M | 211.67M | 208.21M |
| InvestedCapital | 137.25M | 126.48M | 211.67M | 208.21M |
| WorkingCapital | 127.05M | 115.22M | 197.13M | 199.01M |
| NetTangibleAssets | 137.25M | 126.48M | 211.67M | 208.21M |
| CapitalLeaseObligations | 24.18M | 26.27M | 28.55M | 2.06M |
| CommonStockEquity | 137.25M | 126.48M | 211.67M | 208.21M |
| TotalCapitalization | 137.25M | 126.48M | 211.67M | 208.21M |
| TotalEquityGrossMinorityInterest | 137.25M | 126.48M | 211.67M | 208.21M |
| StockholdersEquity | 137.25M | 126.48M | 211.67M | 208.21M |
| GainsLossesNotAffectingRetainedEarnings | 47.00K | 15.00K | -68.00K | -45.00K |
| OtherEquityAdjustments | 47.00K | 15.00K | -68.00K | -45.00K |
| RetainedEarnings | -783.45M | -658.75M | -562.74M | -476.76M |
| AdditionalPaidInCapital | 920.61M | 785.20M | 774.45M | 685.01M |
| CapitalStock | 40.00K | 20.00K | 20.00K | 7.00K |
| CommonStock | 40.00K | 20.00K | 20.00K | 7.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 51.42M | 38.46M | 48.59M | 24.17M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 21.16M | 23.94M | 26.08M | 568.00K |
| OtherNonCurrentLiabilities | 96.00K | |||
| LongTermDebtAndCapitalLeaseObligation | 21.16M | 23.94M | 25.98M | 568.00K |
| LongTermCapitalLeaseObligation | 21.16M | 23.94M | 25.98M | 568.00K |
| CurrentLiabilities | 30.26M | 14.52M | 22.51M | 23.60M |
| OtherCurrentLiabilities | 3.15M | 24.00K | 14.00K | 35.00K |
| CurrentDeferredLiabilities | 0.00 | 8.08M | ||
| CurrentDeferredRevenue | 0.00 | 8.08M | ||
| CurrentDebtAndCapitalLeaseObligation | 3.02M | 2.32M | 2.56M | 1.50M |
| CurrentCapitalLeaseObligation | 3.02M | 2.32M | 2.56M | 1.50M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.22M | 5.95M | 8.37M | 3.08M |
| PayablesAndAccruedExpenses | 17.87M | 6.25M | 11.56M | 10.91M |
| CurrentAccruedExpenses | 13.63M | 4.21M | 8.32M | 6.44M |
| Payables | 4.24M | 2.03M | 3.24M | 4.46M |
| AccountsPayable | 4.24M | 2.03M | 3.24M | 4.46M |
| TotalAssets | 188.66M | 164.94M | 260.25M | 232.38M |
| TotalNonCurrentAssets | 31.36M | 35.20M | 40.61M | 9.77M |
| OtherNonCurrentAssets | 2.32M | 2.04M | 2.01M | 2.16M |
| NetPPE | 29.04M | 33.16M | 38.61M | 7.60M |
| AccumulatedDepreciation | -13.03M | -12.73M | -10.96M | -11.66M |
| GrossPPE | 42.07M | 45.90M | 49.56M | 19.27M |
| Leases | 470.00K | 481.00K | 384.00K | 4.71M |
| ConstructionInProgress | 879.00K | 410.00K | 1.72M | 1.49M |
| OtherProperties | 38.70M | 42.68M | 45.37M | 11.86M |
| MachineryFurnitureEquipment | 2.02M | 2.33M | 2.10M | 1.20M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 157.30M | 129.73M | 219.64M | 222.61M |
| OtherCurrentAssets | 1.65M | 2.11M | 3.00M | 8.71M |
| PrepaidAssets | 6.73M | 3.98M | 2.91M | 6.01M |
| Receivables | 0.00 | 110.00K | ||
| AccountsReceivable | 0.00 | 110.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 148.92M | 123.64M | 213.72M | 207.78M |
| OtherShortTermInvestments | 68.69M | 49.62M | 58.34M | 88.64M |
| CashAndCashEquivalents | 80.23M | 74.02M | 155.38M | 119.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -100.67M | -95.69M | -100.99M | -79.05M |
| RepurchaseOfCapitalStock | -5.11M | 0.00 | ||
| RepaymentOfDebt | -473.00K | 0.00 | -66.00K | 0.00 |
| IssuanceOfDebt | 0.00 | 2.14M | 0.00 | |
| IssuanceOfCapitalStock | 127.23M | 2.97M | 72.55M | 134.88M |
| CapitalExpenditure | -654.00K | -1.51M | -3.02M | -1.28M |
| EndCashPosition | 82.19M | 75.85M | 157.22M | 121.21M |
| BeginningCashPosition | 75.85M | 157.22M | 121.21M | 155.07M |
| ChangesInCash | 6.34M | -81.37M | 36.01M | -33.87M |
| FinancingCashFlow | 122.44M | 3.12M | 74.83M | 134.99M |
| CashFlowFromContinuingFinancingActivities | 122.44M | 3.12M | 74.83M | 134.99M |
| ProceedsFromStockOptionExercised | 794.00K | 148.00K | 203.00K | 107.00K |
| NetCommonStockIssuance | 122.12M | 2.97M | 72.55M | 134.88M |
| CommonStockPayments | -5.11M | 0.00 | ||
| CommonStockIssuance | 127.23M | 2.97M | 72.55M | 134.88M |
| NetIssuancePaymentsOfDebt | -473.00K | 0.00 | 2.08M | 0.00 |
| NetLongTermDebtIssuance | -473.00K | 0.00 | 2.08M | 0.00 |
| LongTermDebtPayments | -473.00K | 0.00 | -66.00K | 0.00 |
| LongTermDebtIssuance | 0.00 | 2.14M | 0.00 | |
| InvestingCashFlow | -16.09M | 9.69M | 59.16M | -91.09M |
| CashFlowFromContinuingInvestingActivities | -16.09M | 9.69M | 59.16M | -91.09M |
| NetInvestmentPurchaseAndSale | -15.44M | 11.20M | 30.05M | -89.81M |
| SaleOfInvestment | 188.90M | 128.63M | 212.81M | 51.44M |
| PurchaseOfInvestment | -204.34M | -117.43M | -182.76M | -141.25M |
| NetBusinessPurchaseAndSale | 0.00 | 31.52M | 0.00 | |
| SaleOfBusiness | 0.00 | 31.52M | 0.00 | |
| NetPPEPurchaseAndSale | -649.00K | -1.51M | -2.42M | -1.28M |
| SaleOfPPE | 5.00K | 0.00 | 600.00K | 0.00 |
| PurchaseOfPPE | -654.00K | -1.51M | -3.02M | -1.28M |
| OperatingCashFlow | -100.01M | -94.18M | -97.98M | -77.76M |
| CashFlowFromContinuingOperatingActivities | -100.01M | -94.18M | -97.98M | -77.76M |
| ChangeInWorkingCapital | 2.85M | -8.87M | -3.69M | -23.04M |
| ChangeInOtherWorkingCapital | -8.08M | -12.64M | ||
| ChangeInOtherCurrentLiabilities | -1.68M | -1.74M | ||
| ChangeInPayablesAndAccruedExpense | 6.97M | -7.73M | 586.00K | -1.05M |
| ChangeInAccruedExpense | 4.77M | -6.97M | 5.83M | -2.25M |
| ChangeInPayable | 2.21M | -764.00K | -5.25M | 1.21M |
| ChangeInAccountPayable | 2.21M | -764.00K | -5.25M | 1.21M |
| ChangeInPrepaidAssets | -2.44M | 598.00K | 3.69M | -9.25M |
| ChangeInReceivables | 0.00 | 110.00K | -110.00K | |
| ChangesInAccountReceivables | 0.00 | 110.00K | -110.00K | |
| OtherNonCashItems | 7.70M | 2.90M | -18.48M | -81.00K |
| StockBasedCompensation | 10.52M | 7.62M | 7.54M | 13.37M |
| AmortizationOfSecurities | -3.59M | -2.41M | 233.00K | 1.12M |
| DepreciationAmortizationDepletion | 2.46M | 2.58M | 2.41M | 2.96M |
| DepreciationAndAmortization | 2.46M | 2.58M | 2.41M | 2.96M |
| Depreciation | 2.46M | 2.58M | 2.41M | 2.96M |
| OperatingGainsLosses | 4.75M | 374.00K | 92.00K | |
| GainLossOnInvestmentSecurities | 4.75M | |||
| GainLossOnSaleOfPPE | 374.00K | 0.00 | 92.00K | |
| NetIncomeFromContinuingOperations | -124.70M | -96.02M | -85.98M | -72.19M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SLDB
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|